Stephen J. Schuster
Hospital of the University of Pennsylvania · 832 works · 34,253 citations · h-index 78
Top works
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- Utility of FDG-PET scanning in lymphoma by WHO classification
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- REDUCTION IN IMMUNOSUPPRESSION AS INITIAL THERAPY FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: ANALYSIS OF PROGNOSTIC VARIABLES AND LONG-TERM FOLLOW-UP OF 42 ADULT PATIENTS1
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- Outcomes of patients with relapsed/refractory diffuse large B‐cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era
- Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation
- Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
- Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
- PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
- Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
- International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
- Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
- Treatment of PTLD with Rituximab or Chemotherapy
- Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience